Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients

Ilaria Iacobucci, Giuseppe Saglio, Gianantonio Rosti, Nicoletta Testoni, Fabrizio Pane, Marilina Amabile, Angela Poerio, Simona Soverini, Simona Bassi, Daniela Cilloni, Renato Bassan, Massimo Breccia, Francesco Lauria, Barbara Izzo, Serena Merante, Francesco Frassoni, Stefania Paolini, Enrico Montefusco, Michele Baccarani, Giovanni Martinelli

Research output: Contribution to journalArticle

Abstract

Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL transcripts. CCgR is durable in the majority of patients but relapse occurs in a subset. Experimental Design: To determine the potential of quantitative reverse transcription-PCR of BCR-ABL to predict cytogenetic relapse, we serially monitored residual disease in 97 CML patients with an imatinib-induced CCgR. Patients with late chronic phase CML after IFN-αfailure were treated with imatinib (400 mg daily). Results: During the imatinib median follow-up time of 36 months (range, 12-54 months), disease monitoring occurred by cytogenetics and quantitative PCR. Twenty percent of patients experienced cytogenetic relapse at a median of 18 months after CCgR and a median of 24 months after starting imatinib. None of the possible prognostic factors studied in univariate and multivariate analyses seemed to predict for loss of cytogenetic response but the reduction of BCR-ABL transcript levels at the time of CCgR is an important prognostic factor. Conclusions: In our study, we showed not only that achieving a major molecular remission at 12 months is predictive of a durable cytogenetic remission but also that patients who achieved a major molecular remission (expressed both as the BCR-ABL/β2 microglobulin ratio %

Original languageEnglish
Pages (from-to)3037-3042
Number of pages6
JournalClinical Cancer Research
Volume12
Issue number10
DOIs
Publication statusPublished - May 15 2006

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Leukemia, Myeloid, Chronic Phase
Recurrence
Imatinib Mesylate
Polymerase Chain Reaction
Reverse Transcription
Research Design
Multivariate Analysis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. / Iacobucci, Ilaria; Saglio, Giuseppe; Rosti, Gianantonio; Testoni, Nicoletta; Pane, Fabrizio; Amabile, Marilina; Poerio, Angela; Soverini, Simona; Bassi, Simona; Cilloni, Daniela; Bassan, Renato; Breccia, Massimo; Lauria, Francesco; Izzo, Barbara; Merante, Serena; Frassoni, Francesco; Paolini, Stefania; Montefusco, Enrico; Baccarani, Michele; Martinelli, Giovanni.

In: Clinical Cancer Research, Vol. 12, No. 10, 15.05.2006, p. 3037-3042.

Research output: Contribution to journalArticle

Iacobucci, I, Saglio, G, Rosti, G, Testoni, N, Pane, F, Amabile, M, Poerio, A, Soverini, S, Bassi, S, Cilloni, D, Bassan, R, Breccia, M, Lauria, F, Izzo, B, Merante, S, Frassoni, F, Paolini, S, Montefusco, E, Baccarani, M & Martinelli, G 2006, 'Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients', Clinical Cancer Research, vol. 12, no. 10, pp. 3037-3042. https://doi.org/10.1158/1078-0432.CCR-05-2574
Iacobucci, Ilaria ; Saglio, Giuseppe ; Rosti, Gianantonio ; Testoni, Nicoletta ; Pane, Fabrizio ; Amabile, Marilina ; Poerio, Angela ; Soverini, Simona ; Bassi, Simona ; Cilloni, Daniela ; Bassan, Renato ; Breccia, Massimo ; Lauria, Francesco ; Izzo, Barbara ; Merante, Serena ; Frassoni, Francesco ; Paolini, Stefania ; Montefusco, Enrico ; Baccarani, Michele ; Martinelli, Giovanni. / Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 10. pp. 3037-3042.
@article{241b53fb87054c99a908eed8de6e7879,
title = "Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients",
abstract = "Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL transcripts. CCgR is durable in the majority of patients but relapse occurs in a subset. Experimental Design: To determine the potential of quantitative reverse transcription-PCR of BCR-ABL to predict cytogenetic relapse, we serially monitored residual disease in 97 CML patients with an imatinib-induced CCgR. Patients with late chronic phase CML after IFN-αfailure were treated with imatinib (400 mg daily). Results: During the imatinib median follow-up time of 36 months (range, 12-54 months), disease monitoring occurred by cytogenetics and quantitative PCR. Twenty percent of patients experienced cytogenetic relapse at a median of 18 months after CCgR and a median of 24 months after starting imatinib. None of the possible prognostic factors studied in univariate and multivariate analyses seemed to predict for loss of cytogenetic response but the reduction of BCR-ABL transcript levels at the time of CCgR is an important prognostic factor. Conclusions: In our study, we showed not only that achieving a major molecular remission at 12 months is predictive of a durable cytogenetic remission but also that patients who achieved a major molecular remission (expressed both as the BCR-ABL/β2 microglobulin ratio {\%}",
author = "Ilaria Iacobucci and Giuseppe Saglio and Gianantonio Rosti and Nicoletta Testoni and Fabrizio Pane and Marilina Amabile and Angela Poerio and Simona Soverini and Simona Bassi and Daniela Cilloni and Renato Bassan and Massimo Breccia and Francesco Lauria and Barbara Izzo and Serena Merante and Francesco Frassoni and Stefania Paolini and Enrico Montefusco and Michele Baccarani and Giovanni Martinelli",
year = "2006",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-05-2574",
language = "English",
volume = "12",
pages = "3037--3042",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients

AU - Iacobucci, Ilaria

AU - Saglio, Giuseppe

AU - Rosti, Gianantonio

AU - Testoni, Nicoletta

AU - Pane, Fabrizio

AU - Amabile, Marilina

AU - Poerio, Angela

AU - Soverini, Simona

AU - Bassi, Simona

AU - Cilloni, Daniela

AU - Bassan, Renato

AU - Breccia, Massimo

AU - Lauria, Francesco

AU - Izzo, Barbara

AU - Merante, Serena

AU - Frassoni, Francesco

AU - Paolini, Stefania

AU - Montefusco, Enrico

AU - Baccarani, Michele

AU - Martinelli, Giovanni

PY - 2006/5/15

Y1 - 2006/5/15

N2 - Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL transcripts. CCgR is durable in the majority of patients but relapse occurs in a subset. Experimental Design: To determine the potential of quantitative reverse transcription-PCR of BCR-ABL to predict cytogenetic relapse, we serially monitored residual disease in 97 CML patients with an imatinib-induced CCgR. Patients with late chronic phase CML after IFN-αfailure were treated with imatinib (400 mg daily). Results: During the imatinib median follow-up time of 36 months (range, 12-54 months), disease monitoring occurred by cytogenetics and quantitative PCR. Twenty percent of patients experienced cytogenetic relapse at a median of 18 months after CCgR and a median of 24 months after starting imatinib. None of the possible prognostic factors studied in univariate and multivariate analyses seemed to predict for loss of cytogenetic response but the reduction of BCR-ABL transcript levels at the time of CCgR is an important prognostic factor. Conclusions: In our study, we showed not only that achieving a major molecular remission at 12 months is predictive of a durable cytogenetic remission but also that patients who achieved a major molecular remission (expressed both as the BCR-ABL/β2 microglobulin ratio %

AB - Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL transcripts. CCgR is durable in the majority of patients but relapse occurs in a subset. Experimental Design: To determine the potential of quantitative reverse transcription-PCR of BCR-ABL to predict cytogenetic relapse, we serially monitored residual disease in 97 CML patients with an imatinib-induced CCgR. Patients with late chronic phase CML after IFN-αfailure were treated with imatinib (400 mg daily). Results: During the imatinib median follow-up time of 36 months (range, 12-54 months), disease monitoring occurred by cytogenetics and quantitative PCR. Twenty percent of patients experienced cytogenetic relapse at a median of 18 months after CCgR and a median of 24 months after starting imatinib. None of the possible prognostic factors studied in univariate and multivariate analyses seemed to predict for loss of cytogenetic response but the reduction of BCR-ABL transcript levels at the time of CCgR is an important prognostic factor. Conclusions: In our study, we showed not only that achieving a major molecular remission at 12 months is predictive of a durable cytogenetic remission but also that patients who achieved a major molecular remission (expressed both as the BCR-ABL/β2 microglobulin ratio %

UR - http://www.scopus.com/inward/record.url?scp=33744798191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744798191&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-2574

DO - 10.1158/1078-0432.CCR-05-2574

M3 - Article

C2 - 16707599

AN - SCOPUS:33744798191

VL - 12

SP - 3037

EP - 3042

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -